Takeda Pharmaceutical Company Limited

Bayer Pharmaceuticals Corporation

Bayer Healthcare LLC

Erasca, Inc.

E. & J. Gallo Winery

Bellwether Coffee Co.

Midiagnostics Nv

Benjamin Jones

Andre A Kiryanov

Barton W Phillips

Sean Timothy Murphy

Jacques P Dumas

Jason W Brown

Xiaolun Wang

Anthony R Gangloff

Marion Lanier

Andrew John Jennings

Joanne Miura

Anthony Ivetac

Chengzhi Zhang

Zhe Nie

Wendy Lee

Gaetan H Ladouceur

Betty Lam

Jianmei Fan

Zhi Chen

Qing Dong

Christopher Ronald Smith

Yasuyoshi Arikawa

Jeffrey Alan Stafford

Jun Feng

Stephen W Kaldor

Jean-Michel Andre Vernier

Steven R Magnuson

Qian Zhao

Ping Chen

Julie A Dixon

Holia Hatoum-Mokdad

Harold C E Kluender

Roger Astbury Smith

Zhe Li

William Johnston Scott

Holger Monenschein

Gan Wang

Huikai Sun

Maria Hopkins

Sheldon Cao

Thomas Nixey

John S Tyhonas

Alex Lee

Neil Vesco

Srinivasa Reddy Natala

Jon Kuehler

Melinda Davis

Dongping Fan

Michael J Burke

Victoria Feher

Masashi Takahashi

Brent Chandler

Catherine R Brennan

Scott Wilhelm

Michael Brands

Karl Miranda

Donald Bierer

Wenlang Fu

Andrea McClure

Marcos Gonzalez-Lopez

Nicholas A Isley

Yan Liu

Stephen Boyer

Victor T Escobedo

Henry D'Souza

John Sandhu

Ricardo Lopez

Jianqing Chen

Walter Keung

Craig A Behnke

Arno Holschuh

Jason Green

Takashi Ichikawa

Brandon McLaughlin

David Kortbawi

Srinivasa Ready Natala

Robert Ruijssenaars

Jennifer Brady

Royal Addis

Laura Hoffman

Doug Thompson

Sean Murphy

Chrisopher McBride

Christopher Mcbride

Sheldon X Cao

Andrea Mcclure

Harold C Kluender

Christopher Smith

Lam Betty

Tricyclic pyridones and pyrimidones

Compounds with KRAS G12C inhibitory active are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation.

Disclosed are compounds of Formula 1 and pharmaceutically acceptable salts thereof, wherein L, R, R, R, R, R, X, X, X, X, X, and Z are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with GPR6.

Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6

The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.

6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD

A bean roasting system includes a roasting chamber, a blower, a variable diverter and a controller. The roasting chamber, the blower and the variable diverter each is disposed at least partially within a recirculating gas flow path. The blower is configured to provide a flow stream of gas through the recirculating gas flow path. The variable diverter is configured to split the gas flow path into at least two flow paths including a treated flow path and a bypass flow path. The treated flow path includes a series arrangement of a gas heater and a catalytic converter. The variable diverter is configured to control a percentage of a flow stream of gas that is diverted into the bypass flow path. The controller is configured to activate different predetermined operating modes for the bean roasting system by controlling a state of the variable diverter and a state of the heater.

Roasting system with clean emissions and high thermal efficiency

6-(5-hydroxy-1H-pyrazol-1-YL)nicotinamide inhibitors of PHD

The present invention provides a method and apparatus for a wine bottle packaging divider and display. The method and apparatus comprise of a divider with opposing side edges and opposing top and bottom edges. The divider has a partitioning line dividing the divider into a first section and a second section, wherein at least one of the first section and the second section is capable of displaying an advertisement. The divider also has at least one pair of elongated openings, wherein each of the at least one pair of elongated openings has an end in proximity to one of the opposing top and bottom edges, wherein said at least one pair of elongated openings is capable of being opened to the one edge and slidably coupled onto a vertical wall for displaying the advertisement. The divider is folded along the partitioning line to fit within a container for packaging the glass bottles.

Method and apparatus for wine bottle packaging and display

The present invention provides a method of treating acute heart failure by administering a compound of the formula: or a pharmaceutically acceptable salt thereof.

Disclosed are compounds of the following formula: in which R, R, R, R, R, R, u, and X are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.

Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP)

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L, L, R, R, R, and Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

Fused heteroaromatic pyrrolidinones as SYK inhibitors

Fused heteroaromatic pyrrolidinones

The present invention provides compounds of the formula:  which are useful as inhibitors of PHD and pharmaceutical compositions thereof.

Disclosed are compounds of the following formula: 

Substituted pyrido[2,3-b]pyrazines

Disclosed are compounds of the following formula: in which R, R, R, R, R, X, and q are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.

Substituted derivatives of pyrido[3,2-e][1,4]thiazino[4,3-a]pyrazine and pyrido[3,2-e][1,4]oxazino[4,3-a]pyrazine

Growing community of inventors

Cardiff-by-the-Sea, CA, United States of America

Benjamin Jones